Research Article

Punica granatum L. Leaf Extract Attenuates Lung Inflammation in Mice with Acute Lung Injury

Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, 1,2,3 Jaciara Sá Gonçalves, 1 Ádylla Wilenna Alves Dourado, 1 Eduardo Martins de Sousa, 1 Natilene Mesquita Brito, 4 Lanna Karinny Silva, 4 Marisa Cristina Aranha Batista, 5 Joicy Cortez de Sá, 5 Cinara Regina Aragão Vieira Monteiro, 1,7 Elizabeth Soares Fernandes, 1 Valério Monteiro-Neto 10,1,7 Lee Ann Campbell, 8 Patrícia Maria Wziack Zago, 9 and Lidio Gonçalves Lima-Neto 11,1,2

1Programa de Pós-Graduação, Universidade CEUMA, São Luís, MA, Brazil
2Programa de Pós-Graduação da Rede BIONORTE, Universidade Federal do Amazonas, Manaus, AM, Brazil
3Departamento de Farmácia, Faculdade Pitágoras, São Luís, MA, Brazil
4Laboratório de Estudos Ambientais, Instituto Federal do Maranhão, São Luís, MA, Brazil
5Laboratório de Farmacognosia I, Universidade Federal do Maranhão, São Luís, MA, Brazil
6Departamento de Medicina, Universidade CEUMA, São Luís, MA, Brazil
7Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, MA, Brazil
8Department of Global Health, University of Washington, Seattle, WA, USA
9Departamento de Odontologia, Universidade CEUMA, São Luís, MA, Brazil

Correspondence should be addressed to Lidio Gonçalves Lima-Neto; lidio.neto@outlook.com

Received 25 August 2017; Revised 10 December 2017; Accepted 18 December 2017; Published 20 February 2018

Copyright © 2018 Aruanã Joaquim Matheus Costa Rodrigues Pinheiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The hydroalcoholic extract of Punica granatum (pomegranate) leaves was previously demonstrated to be anti-inflammatory in a rat model of lipopolysaccharide- (LPS-) induced acute peritonitis. Here, we investigated the anti-inflammatory effects of the ethyl acetate fraction obtained from the pomegranate leaf hydroalcoholic extract (EAFPg) on the LPS-induced acute lung injury (ALI) mouse model. Male Swiss mice received either EAFPg at different doses or dexamethasone (per os) prior to LPS intranasal instillation. Vehicle-treated mice were used as controls. Animals were culled at 4 h after LPS challenge, and the bronchoalveolar lavage fluid (BALF) and lung samples were collected for analysis. EAFPg and kaempferol effects on NO and cytokine production by LPS-stimulated RAW 264.7 macrophages were also investigated. Pretreatment with EAFPg (100–300 mg/kg) markedly reduced cell accumulation (specially neutrophils) and collagen deposition in the lungs of ALI mice. The same animals presented with reduced lung and BALF TNF-α and IL-1β expression in comparison with vehicle controls (p < 0.05). Additionally, incubation with either EAFPg or kaempferol (100 μg/ml) reduced NO production and cytokine gene expression in cultured LPS-treated RAW 264.7 macrophages. Overall, these results demonstrate that the prophylactic treatment with EAFPg attenuates acute lung inflammation. We suggest this fraction may be useful in treating ALI.

1. Introduction

Acute lung injury (ALI) is a clinical condition that causes disruption of the lung endothelial tissue and epithelial barrier and loss of lung function [1, 2]. ALI incidence remains high, and it is associated with high rates of mortality and morbidity worldwide, especially in developing countries [3]. ALI is characterized by intense transepithelial leukocyte infiltration, exudate accumulation in the lungs, loss of integrity of the alveolar-capillary membrane, and tissue damage [4]. This
response has been suggested to be due to the increased production of inflammatory mediators including cytokines (TNF-α, IL-1β, and IL-6), especially by alveolar macrophages and neutrophils [5].

Punica granatum L. (pomegranate) has been shown to possess wound healing, antimicrobial, antioxidant, and anti-inflammatory properties [6-8]. Especially due to its anti-inflammatory activities, pomegranate is traditionally used to treat infections. In this context, we recently demonstrated that the leaf hydroalcoholic extract obtained from pomegranate is anti-inflammatory as it inhibits TNF-α production and decreases neutrophil migration in a rat model of lipopolysaccharide- (LPS-) induced acute peritonitis [8]. Furthermore, Haseeb et al. showed that the pomegranate fruit extract attenuates IL-6 production, reactive oxygen species, IL-1β-mediated phosphorylation of the inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ), expression of IKKβ mRNA, degradation of IκBα, and the activation and nuclear translocation of NF-κB/p65 in human chondrocytes [9].

To date, pomegranate effects on acute lung inflammation have not been yet investigated. Here, we assessed the anti-inflammatory potential of the ethyl acetate fraction (EAFPg) obtained from a pomegranate leaf hydroalcoholic extract in a mouse model of LPS-induced acute lung injury.

2. Material and Methods

2.1. Plant Material and Preparation of EAFPg. Fresh leaves of Punica granatum L. were collected at the Ático Seara Herbarium of the Universidade Federal do Maranhão in São Luís, Maranhão, Brazil [8], and a voucher specimen was deposited (voucher number 01002). The leaf hydroalcoholic extract was prepared, and the EAFPg was obtained as previously described [8].

2.2. HPLC-DAD-ESI-IT/MS Analysis. The chemical constituents of EAFPg were analyzed in a high-performance liquid chromatography (HPLC) system (LC-10AD, Shimadzu) equipped with a photodiode array detector coupled to an Esquire 3000 Plus ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany), using electrospray ionization (ESI) as previously described [10]. Separation was performed using a Phenomenex Kinetex C-18 column (250 × 4.6 mm, 5 μm; Torrance, CA, USA). The column oven was maintained at room temperature. The HPLC was set up with an elution gradient as follows: 0–2 min, 5% B; 2–10 min, 5–25% B; 10–20 min, 25–40% B; 20–30 min, 40–50% B; 30–40 min, 50–60% B; and 40–50 min, 70–100% B. Acetic acid (2%) in Milli-Q water was used as mobile phase A, and methanol was used as mobile phase B. The injection volume consisted of 25 μl of the reconstituted sample at 5 mg/ml, with a flow rate of 0.6 ml/min. Detection was achieved in a diode array detector (DAD) at 200–500 nm and with direct mass spectrometry/mass spectrometry, a method in negative electrospray (-ESI) mode with a detector voltage maintained at 4.0 kV, ion source at 40 V, and capillary temperature at 320°C. The nebulizing gas was nitrogen (N2) flowing at 7 ml/min, a sheath gas provided at a pressure of 27 psi, while helium was used as the collision gas. Analyses were carried out using full-scan mass spectra and data-dependent MS2 scans from m/z 100 to 2000. The compounds were identified on the basis of their molecular ion mass fragmentation. The obtained mass spectrum was compared with that of the literature.

2.3. In Vivo Assays

2.3.1. Animals. Sixty-six nonfasted male outbred Swiss mice (20–30 g) were used. Mice were obtained from the animal facility of Universidade CEUMA (UNICEUMA) and were kept in a climatically controlled environment (room temperature of 22 ± 2°C and humidity of around 60%) under 12:12 h light-dark cycle (lights on 07:00 a.m.). All procedures were approved by the Ethics Committee of UNICEUMA (April 24, 2014; #017/2014) and carried out in accordance with the Brazilian Society for Animal Welfare (SBCAL).

2.3.2. Induction of LPS-Induced ALI and Pharmacological Treatments. Animals were randomly distributed into six groups (n = 6/group) for lung analysis and five groups (n = 6/group) for bronchoalveolar lavage fluid (BALF) analysis. Mice received a single oral administration (p.o.) of vehicle (saline, 10 ml/kg), EAFPg (30–300 mg/kg), or dexamethasone (5 mg/kg) 30 min prior to LPS challenge. ALI was induced by a single intranasal (i.n.) instillation of LPS (30,000 EU in 50 μl/animal and 25 μl/narine). Vehicle-treated mice were used as controls. Four hours after the challenge, mice were culled by anesthetic overdose with ketamine (120 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), and the bronchoalveolar lavage fluid (BALF) was collected. For this, the trachea of each mouse was cannulated and the alveoli were washed three times with 0.5 ml of ice-cold phosphate buffered saline (PBS) containing 0.5% sodium citrate. An aliquot of the BALF was separated and used for quantification of leukocyte counts and the rest centrifuged at 400 × g for 10 min at 4°C. The supernatant was immediately frozen and stored at −80°C for further analysis. In a separate series of experiments, the lungs were collected from animals that did not undergo BALF collection and were processed for histological analysis.

2.3.3. Total and Differential Leukocyte Counts in BALF Samples. Total cell counts were performed in a Neubauer chamber and microscope (Zeiss Axio Imager Z2 upright microscope, Carl Zeiss, Göttingen, Germany) after diluting an aliquot of the BALF with Türk solution (1:20). Another aliquot (50 μl) was used for differential cell counts. For this, the slides were stained with May–Grünwald Giemsa and then analyzed by microscopy in an immersion objective. A minimum of 200 leukocytes was considered. Two independent researchers performed blinded analyses; if there was discordance, a third researcher performed the analysis.

2.3.4. RT-qPCR Assays in the Lung Tissue. TNF-α, IL-6, IL-1β, and IL-10 mRNA expression in lung samples was determined by RT-qPCR. Total RNA was extracted by using a RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions in a QIAcube automatic DNA extractor (Qiagen, Hilden, Germany). Samples were
treated with DNase (Qiagen, Hilden, Germany) and then reverse-transcribed using 200 U of SuperScript II reverse transcriptase (Thermo Fisher Scientific) to obtain cDNA. The qPCR assays were carried out in 96-well plates using a double-stranded DNA dye (GoTaq® real-time PCR Master Mix from Promega) in a QuantStudio™ 6 flex real-time PCR instrument as previously described. GAPDH mRNA was used as an endogenous reference gene. mRNA relative expression was calculated using the \( 2^{-\Delta Ct} \) method [11]. Results represent the mean values obtained from two independent experiments, with assays performed in triplicate.

2.3.5. Cytokine Levels in BALF Samples. BALF TNF-α and IL-10 protein levels were analyzed in enzyme-linked immunosorbent assay kits according to the manufacturer’s instructions (R&D Systems). Sample readings for each cytokine were compared with those of a standard curve (0–800 pg/ml). Results are expressed as protein levels in pg/ml. All experiments were performed in triplicate.

2.3.6. Albumin Levels in BALF Samples. Albumin levels in BALF samples were measured by the Bradford method using the standard Quick Start Bradford Protein Assay Kit from Bio-Rad (Hercules, California) according to the manufacturer’s instructions. Albumin was measured as it is an indicator of plasma extravasation. Absorbance was measured in an automated spectrophotometer at 650 nm. Readings obtained for each individual experiment were compared with those of a standard curve of albumin (0–2.0 mg/ml). Results are expressed as mg of albumin per ml of BALF. All experiments were performed in triplicate.

2.3.7. Histological Analysis. The collected lungs were fixed in 10% neutral formalin for 24h and then embedded in paraffin. After deparaffinization and dehydration as previously described [10], sections (4 μm) were stained with hematoxylin and eosin or Masson’s trichrome and analyzed by microscopy under 100x and 400x magnification. The density of leukocytes/unit area (130 μm²) was determined by counting the number of cells on the integrating eyepiece that fell into areas of the bronchioli and distal lung parenchyma using the ImageJ Program. Using the same program, the collagen area was measured also in areas of the bronchioli and distal lung parenchyma. All measurements were performed in ten random sections of 130 μm² per animal at 200x (for collagen area) and 400x magnification (for leukocyte count), and the researcher who performed the analysis was unaware of the experimental group designation. Two independent researchers performed blinded analyses; if there was discordance, a third researcher performed the analysis.

2.4. In Vitro Assays

2.4.1. RAW 264.7 Macrophage Culture and Pharmacological Treatments. RAW 264.7 cells were cultured and maintained in DMEM medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) containing 10% fetal bovine serum and 1% antibiotic solution—1000 U/ml penicillin G and 100 U/ml streptomycin sulfate (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Cells (1 × 10⁵ cells/well) were treated with EAFPg (50–100 μg/ml), kaempferol (25–100 μg/ml), or dexamethasone (2–4 μg/ml) and stimulated with LPS (10 μg/ml; 30,000 EU/well/100 μl; Sigma, St. Louis, MI, USA), at noncytotoxic concentrations. Then, cells were incubated for 48 h at 37°C and 5% CO₂. Vehicle- (1% DMSO in PBS) treated cells were used as controls.

2.4.2. RT-qPCR Assays in RAW 264.7 Murine Macrophages. TNF-α, IL-6, IL1-β, and IL-10 mRNA expression was evaluated in RAW 264.7 cells by RT-qPCR as described in Section 2.3.4.

2.4.3. NO Levels in Cell Culture Supernatants. The production of NO was determined by measuring nitrite as previously described [7]. Briefly, cell supernatants were incubated with an equal volume of a Griess reagent (Sigma, St. Louis, MI, USA), and the absorbance was determined at 540 nm and compared with that obtained from a NO₂ standard curve (0–300 μM). Results are expressed as μM of NO₂.

2.5. Statistical Analysis. Data are expressed as mean ± standard deviation (SD). Differences between groups were analyzed by one-way analysis of variance (ANOVA), followed by the Newman-Keuls multiple comparison test. Percentages of inhibition were calculated as the mean of the inhibitions obtained for each individual experiment. \( p \) values < 0.05 were considered statistically significant.

3. Results

3.1. Phytochemical Analysis of EAFPg. Figure 1 shows the HPLC analytical plot for EAFPg at 327 nm (a) and the detected components (b). These included punicalin (peak 1; retention time: 11.2 min), ellagic acid derivative (peak 2; retention time: 12.3 min), galloyl-HHDP-glucose (peak 3; retention time: 17.4 min), castalagin derivative (peaks 4 and 5; retention times: 23.6 and 26.6 min, resp.), granatin B (peak 6; retention time: 26.7 min), ellagic acid rhamnoside (peak 7; retention time: 32.2 min), kaempferol-3-O-glucoside (peak 8; retention time: 32.7 min), kaempferol derivative (peak 9; retention time: 34.9 min), and kaempferol-arabinoside (peak 10; retention time: 38.3 min).

3.2. EAFPg Reduces Leukocyte Accumulation and Collagen Deposition into the Lungs of Mice with ALI. Figures 2 and 3 show the effects of EAFPg (30–300 mg/kg) and dexamethasone (5 mg/kg) on the lung tissue of mice with LPS-induced ALI. Animals with ALI exhibited an intense inflammatory cell infiltr in the lungs (Figure 2(b)). The same mice also presented multifocal areas of collagen deposition (Figure 3(b)) in comparison with those which received i.n. saline (Figure 3(a)). LPS-induced pathological changes were not affected by the pretreatment with EAFPg at 30 mg/kg. On the other hand, pretreatment with EAFPg at 100–300 mg/kg markedly reduced the collagen deposition with leukocyte infiltration, with respect to LPS mice treated with vehicle (Figures 2(d), 2(e), 3(d), and 3(e)). Animals pretreated with dexamethasone also displayed attenuated lung inflammation (Figures 2(f) and 3(f)). In addition, EAFPg
(100–300 mg/kg) and dexamethasone markedly diminished the numbers of leukocytes in the bronchial area (12.0 ± 1.0, 13.0 ± 1.0, and 10.3 ± 1.5 leukocytes/130 μm², resp.) (Figure 2(g)) and in the alveolar parenchyma area (109.7 ± 4.7, 66.3 ± 2.5, and 41.3 ± 1.5 leukocytes/130 μm², resp.) when compared with those of the vehicle-treated ALI mice (83.3 ± 1.5 leukocytes/130 μm² and 384.3 ± 3.5 leukocytes/130 μm²). Moreover, EAFPg (100–300 mg/kg) and dexamethasone markedly reduced the bronchial (7.5% ± 0.6%, 7.0% ± 0.1%, and 6.7% ± 0.3%, resp.; Figure 2(g)) and the alveolar parenchyma collagen deposition (3.7% ± 0.5%, 3.3% ± 0.7%, and 2.2% ± 0.2%, resp.) when compared with that of the ALI control group (33.3% ± 10.8% and 11.9% ± 2.7%, resp.).

3.3. EAFPg Reduces TNF-α and IL-1β but Not IL-6 mRNA Expression in the Lungs. LPS instillation significantly increased TNF-α, IL-1β, and IL-6 mRNA expression in the lungs (Figures 4(a)–4(c)). When tested at 30 mg/kg, EAFPg did not affect TNF-α, IL-1β, and IL-6 mRNA expression. On the other hand, 100 and 300 mg/kg EAFPG significantly downregulated lung TNF-α and IL-1β but not IL-6 expression in mice with ALI. Likewise, dexamethasone treatment significantly inhibited the expression of all evaluated cytokines, and the effects of the dexamethasone were significantly higher than those observed for EAFPg.

3.4. Plasma Extravasation and BALF TNF-α Levels Are Reduced in Mice with ALI Treated with EAFPg. Albumin and TNF-α protein levels were augmented in BALF samples obtained from mice with ALI (Figures 5(a) and 5(c)) while IL-10 was reduced (Figure 5(b)). On the other hand, IL-10 was reduced in the BALF from the same animals. Both EAFPg (100 mg/kg) and dexamethasone diminished the levels of TNF-α (219.8 ± 6.4 pg/ml) and albumin (120.6 ± 42.8 pg/ml) in the BALF when compared with those of LPS-challenged mice pretreated with vehicle (397 ± 109.6 and 228.6 ± 41.6 pg/ml, resp.; Figures 5(a) and 5(c)). No effects were observed for either EAFPg or dexamethasone on IL-10 levels in the tested doses (Figure 5(b)).

3.5. EAFPg Prevents Leukocyte Accumulation into the Alveoli. Mice with LPS-induced ALI had increased numbers of total leukocytes in the bronchial area (Figure 2(g)) and in the alveolar parenchyma area (Figure 2(g)) when compared with those of the vehicle-treated ALI mice (83.3 ± 1.5 leukocytes/130 μm² and 384.3 ± 3.5 leukocytes/130 μm²). Moreover, EAFPg (100–300 mg/kg) and dexamethasone markedly reduced the bronchial (7.5% ± 0.6%, 7.0% ± 0.1%, and 6.7% ± 0.3%, resp.; Figure 2(g)) and the alveolar parenchyma collagen deposition (3.7% ± 0.5%, 3.3% ± 0.7%, and 2.2% ± 0.2%, resp.) when compared with that of the ALI control group (33.3% ± 10.8% and 11.9% ± 2.7%, resp.).
Figure 2: Effect of the pretreatment with EAFPg on leukocyte accumulation into the lungs obtained from mice treated with saline (a), LPS (b), 30 mg/kg EAFPg plus LPS (c), 100 mg/kg EAFPg plus LPS (d), 300 mg/kg EAFPg plus LPS (e), or 5 mg/kg dexamethasone plus LPS (f). Leukocyte counts in the bronchial (g) and alveolar parenchyma areas (h). Data is expressed as mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis. *p < 0.05 differs from saline-treated mice; #p < 0.05 differs from vehicle-treated LPS-stimulated mice. Bronchiolar inflammatory cell infiltrates are shown as black arrows. Sections (4 μm) were stained with hematoxylin and eosin. Magnification of 100x and 400x.
Figure 3: Effect of the pretreatment with EAFPg and dexamethasone on the collagen deposition in lung samples obtained from mice treated with saline (a), LPS (b), 30 mg/kg EAFPg plus LPS (c), 100 mg/kg EAFPg plus LPS (d), 300 mg/kg EAFPg plus LPS (e), or 5 mg/kg dexamethasone plus LPS (f). Quantitative analysis of the collagen area (percentage area) in the bronchial (g) and alveolar parenchyma areas (h). Data is expressed as mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis. *p < 0.05 differs from saline-treated mice; #p < 0.05 differs from vehicle-treated LPS-stimulated mice. Collagen areas with leukocyte infiltration are shown as red arrows. Sections (4 μm) were stained with Masson’s trichrome. Magnification of 100x and 400x.
and differential leukocytes in their BALF in comparison with the saline group (Figures 6(a), 6(b), and 6(c)). In contrast, EAFPg (100 mg/kg) pretreated mice with ALI had significantly lower numbers of leukocytes (35,814 ± 12,005 cells/mm³) in their BALF in comparison with vehicle-treated mice (58,733 ± 13,629 cells/mm³, p < 0.0001, see Figure 6(a)). A similar effect was noted for LPS-challenged mice pretreated with dexamethasone (Figure 6(a)). In addition, the number of neutrophils was significantly reduced in LPS-challenged mice pretreated with 100 mg/kg of EAFPg (32,878 ± 11,116 cells/mm³) when compared with vehicle-treated mice (54,813 ± 12,678 cells/mm³, p < 0.0001, see Figure 6(b)). No differences were observed in the number of macrophages between groups (Figure 6(c)).

3.6. EAFPg, Kaempferol, and Dexamethasone Reduce Cytokine mRNA Expression in Cultured RAW 264.7 Macrophages. IL-1β, IL-6, and IL-10 mRNA levels were downregulated by EAFPg (100 μg/ml), kaempferol (25–100 μg/ml), and dexamethasone (2–4 μg/ml) in macrophages activated by LPS (Figures 7(a), 7(b), and 7(c)).

3.7. EAFPg and Kaempferol Reduce NO Release by Macrophages. NO production was reduced in LPS-activated macrophages incubated with EAFPg (100 μg/ml) and kaempferol (25–100 μg/ml) (Figures 8(a) and 8(b), resp.).

4. Discussion

Extracts prepared from pomegranate peels and seeds were described previously to possess anti-inflammatory properties [12, 13]. However, very little is known about the effects of pomegranate leaf extracts or fractions on inflammation. We recently demonstrated that the pomegranate leaf hydroalcoholic extract attenuates LPS-induced peritonitis by decreasing the accumulation of leukocytes and the release of proinflammatory mediators in the peritoneum [8]. We now show that EAFPg protects mice from ALI by reducing lung inflammation.

The phytochemical analysis of EAFPg demonstrated the presence of kaempferol, ellagic acid derivative, and other bioactive molecules, a similar composition to that previously observed for the leaf hydroalcoholic extract [8]. Chen et al. [14] showed that kaempferol significantly blocks LPS-induced activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB). In addition, Cornelio Favarin et al. demonstrated that ellagic acid reduces cyclooxygenase-2- (COX-2-) induced exacerbation of inflammation, vascular permeability changes,
Figure 5: Effects of the pretreatment with EAFPg on TNF-α (a), IL-10 (b), and albumin (c) levels in BALF of the animals divided into six groups. Animals were randomly distributed into five groups (n = 6/group). Mice received in the prophylactic scheme EAFPg (30 mg/kg and 100 mg/kg, p.o.), dexamethasone (DEXA, 5 mg/kg, p.o.), or vehicle (PBS, p.o.). The values are presented as the mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis versus nonpretreated saline-injected mice (*p < 0.05) and versus nonpretreated LPS-installed mice (#p < 0.05).

Figure 6: Effects of the pretreatment with EAFPg on the numbers of total leukocytes (a), neutrophils (b), or macrophages (c) in BALF and total leukocytes in the lungs. Animals were randomly distributed into five groups (n = 6/group). Mice received in the prophylactic scheme EAFPg (30 mg/kg and 100 mg/kg, p.o.), dexamethasone (DEXA, 10 mg/kg, p.o.), or vehicle (PBS, p.o.). The values are presented as the mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis versus nonpretreated saline-injected mice (*p < 0.05) and versus nonpretreated LPS-installed mice (#p < 0.05).
**Figure 7:** Effect of the pretreatment with EAFPg (50–100 μg/ml) or kaempferol (25–100 μg/ml) on IL-6 (a), IL-1β (b), and IL-10 (c) mRNA expression in RAW 264.7 macrophages. Data is expressed as mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis. *p < 0.05 differs from saline-treated cells; †p < 0.05 differs from vehicle-treated LPS-stimulated cells.

**Figure 8:** Effect of the pretreatment with EAFPg (50–100 μg/ml) (a) or kaempferol (25–100 μg/ml) (b) on NO release by RAW 264.7 macrophages. Data is expressed as mean ± SD. Significances were calculated by one-way ANOVA followed by the Newman-Keuls multiple comparison test analysis. *p < 0.05 differs from saline-treated cells; †p < 0.05 differs from vehicle-treated LPS-stimulated cells.
and neutrophil recruitment to the BALF of mice with ALI induced by acid [15]. However, kaempferol was found to be the major component in EAFPg. Thus, we hypothesized that EAFPg is anti-inflammatory probably due to the content of kaempferol in its composition.

In patients with ALI, one of the main pathological changes observed in their lungs is an intense inflammatory infiltration as a consequence of the increased permeability of the alveolar-capillary barrier and epithelial damage. In our study, it was observed that EAFPg suppresses lung inflammation and collagen deposition in the airways of mice intranasally challenged with LPS. Corroborating these findings, de Oliveira et al. [10] showed that the crude extract obtained from pomegranate leaves inhibits the pathological changes induced by ovalbumin in the lung tissue.

The inflammatory infiltration observed in ALI results from intense and persistent inflammation. Initially, the inflammation is provoked by lung-resident macrophages that activate intracellular mediators after interacting with pathogen-associated molecular patterns, such as LPS. It was not observed that increased migration of monocyte-derived macrophages to the lung suggested that 4 hours is not enough for its migration. Large amounts of cytokines were primarily produced and released by lung-resident macrophages in response to LPS [16]. Therefore, to further evaluate the effects of the EAFPg on lung inflammation, we measured the inflammatory markers TNF-α, IL1-β, and IL-6. We found that the pretreatment with EAFPg reduces the gene expression of these mediators in the lung tissue. Additionally, cytokine mRNA expression was potently attenuated in LPS-stimulated macrophages treated with EAFPg or kaempferol. It was previously demonstrated that the hydroalcoholic extract from pomegranate leaves reduces TNF-α mRNA expression in peritoneal leukocytes obtained from rats with LPS-induced peritonitis [8].

TNF-α induces the expression of adhesion molecules on endothelial cells, thus contributing to neutrophil migration. In ALI, neutrophils are the first cells to be recruited into the lungs [17]. In the present study, we demonstrated that EAFPg reduces neutrophil migration into the alveoli. Accordingly, Bouchal et al. [18] showed that an aqueous extract of *P. granatum* peel inhibits neutrophil-mediated myeloperoxidase activity and attenuates LPS-induced lung inflammation in mice. In addition, Marques et al. [8] showed that the numbers of peritoneal leukocytes, especially neutrophils, are reduced in hydroalcoholic extract-treated rats with acute peritonitis.

Taken together, our data demonstrate that EAFPg may be used as food supplements, like tea, to prevent inflammatory disorders in which neutrophils play an essential role, such as ALI. However, further studies are necessary in order to address the effects of EAFPg in later time points of ALI.

**Conflicts of Interest**

The authors declare that there is no commercial or financial relationship that could be construed as a potential conflict of interest.

**Authors’ Contributions**

Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Eduardo Martins de Sousa, Cinara Regina Aragão Vieira Monteiro, Valério Monteiro-Neto, Patrícia Maria Wziack Zago, and Lidio Gonçalves Lima-Neto contributed to the conception and the design of the work. Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Jaciara Sá Gonçalves, Natilene Mesquita Brito, Lanna Karinyin Silva, Ádylla Wilenna Alves Dourado, Elizabeth Soares Fernandes, and Lidio Gonçalves Lima-Neto wrote the manuscript. Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Natilene Mesquita Brito, Lanna Karinyin Silva, and Marisa Cristina Aranha Batista characterized the pomegranate leaf extract. Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Jaciara Sá Gonçalves, Ádylla Wilenna Alves Dourado, Eduardo Martins de Sousa, Natilene Mesquita Brito, Lanna Karinyin Silva, Marisa Cristina Aranha Batista, Joicy Cortez de Sá, Cinara Regina Aragão Vieira Monteiro, Elizabeth Soares Fernandes, Valério Monteiro-Neto, Lee Ann Campbell, and Lidio Gonçalves Lima-Neto wrote the manuscript. Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Natilene Mesquita Brito, Lanna Karinyin Silva, and Marisa Cristina Aranha Batista characterized the pomegranate leaf extract.

**Acknowledgments**

This work was supported by the Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão (FAPEMA, Brazil; no. 00516-14) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil; no. 3325/2013).

**References**

[1] S. Sarwar, Z. S. Lin, C. F. Ku et al., “Protective effect of dihydro-resveratrol against lung injury in rats with cerulein-induced acute pancreatitis,” *Planta Medica*, vol. 81, no. S 01, pp. S1–S381, 2016.

[2] R. Tanaka, Y. Ishima, Y. Enoki et al., “Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice,” *Frontiers in Immunology*, vol. 5, p. 561, 2014.

[3] S. K. Sahetya, E. C. Goligher, and R. G. Brower, “Fifty years of research in ARDS. Setting positive end-expiratory pressure in the acute respiratory distress syndrome,” *American Journal of Respiratory and Critical Care Medicine*, vol. 195, no. 11, pp. 1429–1438, 2017.

[4] T. R. Ramalho, M. T. Oliveira, A. L. Lima, C. R. Bezerra-Santos, and M. R. Piuvezam, “Gamma-terpinene modulates acute inflammatory response in mice,” *Planta Medica*, vol. 81, no. 14, pp. 1248–1254, 2015.

[5] M. I. Bittencourt-Mernak, N. M. Pinheiro, F. P. Santana et al., “Prophylactic and therapeutic treatment with the flavonone sakuranetin ameliorates LPS-induced acute lung injury,” *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 312, no. 2, pp. L217–L230, 2016.
[6] E. P. Lansky and R. A. Newman, “Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer,” Journal of Ethnopharmacology, vol. 109, no. 2, pp. 177–206, 2007.

[7] M. K. Reddy, S. K. Gupta, M. R. Jacob, S. I. Khan, and D. Ferreira, “Antioxidant, antimalarial and antimicrobial activities of tannin-rich fractions, ellagitannins and phenolic acids from Punica granatum L.,” Planta Medica, vol. 73, no. 5, pp. 461–467, 2007.

[8] L. C. Marques, A. J. Pinheiro, J. G. Araujo et al., “Anti-inflammatory effects of a pomegranate leaf extract in LPS-induced peritonitis,” Planta Medica, vol. 82, no. 17, pp. 1463–1467, 2016.

[9] A. Haseeb, N. M. Khan, O. S. Ashruf, and T. M. Haqqi, “A polyphenol-rich pomegranate fruit extract suppresses NF-κB and IL-6 expression by blocking the activation of IKKβ and NIK in primary human chondrocytes,” Phytotherapy Research, vol. 31, no. 5, pp. 778–782, 2017.

[10] J. F. de Oliveira, D. V. Garreto, M. C. da Silva et al., “Therapeutic potential of biodegradable microparticles containing Punica granatum L. (pomegranate) in murine model of asthma,” Inflammation Research, vol. 62, no. 11, pp. 971–980, 2013.

[11] L. G. Lima-Neto, R. D. Hirata, A. D. Luchessi et al., “Chlamydia pneumonia and increased TLR4 gene expression in leukocytes are associated with acute myocardial infarction,” Journal of Biological Regulators and Homeostatic Agents, vol. 28, no. 3, pp. 449–460, 2014.

[12] J. Mo, P. Panichayupakaranant, N. Kaewnopparat, A. Nitiruangjaras, and W. Reanmongkol, “Topical anti-inflammatory and analgesic activities of standardized pomegranate rind extract in comparison with its marker compound ellagic acid in vivo,” Journal of Ethnopharmacology, vol. 148, no. 3, pp. 901–908, 2013.

[13] T. Ismail, P. Sestili, and S. Akhtar, “Pomegranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 397–405, 2012.

[14] X. Chen, X. Yang, T. Liu et al., “Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice,” International Immunopharmacology, vol. 14, no. 2, pp. 209–216, 2012.

[15] D. Cornelio Favarin, M. Martins Teixeira, E. Lemos de Andrade et al., “Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice,” Mediators of Inflammation, vol. 2013, Article ID 164202, 13 pages, 2013.

[16] J. M. Nicholls, L. L. Poon, K. C. Lee et al., “Lung pathology of fatal severe acute respiratory syndrome,” The Lancet, vol. 361, no. 9371, pp. 1773–1778, 2003.

[17] R. Jose, A. Williams, M. Sulikowski, D. Brealey, J. Brown, and R. Chambers, “Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia,” The Lancet, vol. 385, article S52, Supplement 1, 2015.

[18] R. Bachoual, W. Talmoudi, T. Boussetta, F. Braut, and J. El-Benna, “An aqueous pomegranate peel extract inhibits neutrophil myeloperoxidase in vitro and attenuates lung inflammation in mice,” Food and Chemical Toxicology, vol. 49, no. 6, pp. 1224–1228, 2011.